Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2024

Feb 13, 2025

BUY
$6.02 - $9.85 $1.81 Million - $2.96 Million
300,000 New
300,000 $2.16 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $332M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Peak6 LLC Portfolio

Follow Peak6 LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 LLC with notifications on news.